Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer to enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy.

check-cap.com

Check-Cap

Symetryx

Today, Symetryx Corporation ("Symetryx") announced a non-binding proposal to acquire Check-Cap LTD (NASDAQ: CHEK) ("Check") for $4.35 per share in cash.

Symetryx Corp. Announced A Non-Binding Proposal To Acquire Check-Cap For $4.35 Per Share

Description

Company Information

M&A Insights

Symetryx Corp. Announced A Non-Binding Proposal To Acquire Check-Cap For $4.35 Per Share

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Company Information